QLED-PDT: flexible light-emitting bandage for chronic skin inflammation therapy
A flexible 630nm Quantum-dot LED (QLED) bandage that enables long-term, home-based photodynamic therapy for chronic inflammatory skin conditions such as atopic dermatitis. Combines tunable narrow-band light emission with a lightweight, wearable form factor to deliver targeted, non-invasive treatment over 6+ months, reducing hospital visits and costs.
Overview
This solution reimagines photodynamic therapy (PDT) for chronic inflammatory skin conditions by replacing conventional, clinic-based light sources with a flexible Quantum-dot LED (QLED) bandage. Targeted at conditions such as atopic dermatitis and chronic eczema, the approach seeks to deliver sustained, non-invasive treatment that patients can self-administer at home. By integrating QLED's precision light control into a wearable format, the technology aims to reduce inflammation, improve skin health over extended periods, and minimize the need for frequent hospital visits, lowering overall treatment costs while maintaining therapeutic effectiveness.
Technical specifications
- Flexible 630nm QLED light source: Tunable, narrow-band emission optimized for PDT activation of topical photosensitizers such as 5-aminolevulinic acid (ALA).
- Wearable bandage form factor: Lightweight and conformable design intended for comfortable long-term wear on affected skin areas.
- Adjustable treatment parameters: Light intensity, exposure duration, and bandage size can be optimized for individual patient needs and lesion characteristics.
- Targeted, uniform illumination: QLED technology enables consistent light delivery across the treatment area, a critical factor for effective PDT.
- Home-use compatibility: Designed to support daily, non-invasive therapy routines outside of clinical settings.
Technology readiness level
The project is currently at the prototype development stage. The principal investigator has previously demonstrated that 630nm QLED combined with ALA effectively kills cancer cells in preclinical work, and published case evidence supports ALA-PDT efficacy in chronic eczema. The planned development pathway includes: (1) prototype bandage fabrication and design optimization, (2) preclinical efficacy and safety testing in a sponsor-selected animal model, and (3) clinical trial preparation, including regulatory engagement. The technology is not yet validated in humans for this specific application and will require further preclinical and clinical studies before commercialization.
About University of Central Florida
The University of Central Florida is a comprehensive public research university in Orlando and one of the nation’s largest, classified as Carnegie R1. Industry partnerships are enabled by the adjacent Central Florida Research Park and a Health Sciences Campus in Lake Nona Medical City, anchored by a joint‑venture teaching hospital with HCA Healthcare; UCF also co‑leads the Florida High Tech Corridor. A university‑wide co‑op and internship infrastructure connects employers to talent, and the UCF Business Incubation Program offers soft‑landing sites and venture support across multiple locations. Research is backed by competitive federal funding, with DoD, NSF, NASA and NIH among UCF’s top sponsors. A dedicated Office of Technology Transfer streamlines IP protection, licensing and industry agreements, supported by the UCF Research Foundation.
delivered to your inbox.